Welcome to our dedicated page for Madrigal Pharmac SEC filings (Ticker: MDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Madrigal Pharmaceuticals, Inc. filings document the company’s biopharmaceutical business, commercial reporting for Rezdiffra (resmetirom), and governance matters tied to its Nasdaq-listed common stock. Current reports include quarterly results furnished under Item 2.02, updates on Rezdiffra net sales and cash resources, and Regulation FD disclosures related to pipeline and licensing activity in MASH.
Other filings cover material agreements affecting Rezdiffra intellectual property and royalties, including amendments to a research, development and commercialization agreement, as well as proxy disclosures for director classes, board matters, executive compensation and equity incentive plans. The filing record also documents stockholder meeting proposals and corporate-governance actions for a commercial-stage biopharmaceutical company developing metabolic liver-disease therapies.
Janus Henderson Group plc filed an amended Schedule 13G reporting passive ownership of Madrigal Pharmaceuticals common stock. Through its investment adviser subsidiaries managing various client accounts, it may be deemed to beneficially own 1,584,843 shares, representing 7.0% of Madrigal’s common stock as of 12/31/2025.
The asset manager entities hold shared voting and shared dispositive power over these shares, while having no sole voting or dispositive power. Dividends and sale proceeds belong to the underlying managed portfolios, and Janus Henderson certifies the holdings are in the ordinary course of business and not for influencing control.
Madrigal Pharmaceuticals amended its long-standing collaboration with Roche covering Rezdiffra. Effective January 29, 2026, Madrigal gains full and exclusive control over all patent term adjustments and patent term extensions applicable to Rezdiffra, including patents owned by Roche and those jointly owned.
In exchange for this expanded control of Rezdiffra’s patent life, the royalty that Madrigal pays Roche on net sales of Rezdiffra will not be reduced until certain patent term extensions that have been, or could have been, filed have expired. The amendment is documented in a First Amendment agreement filed as an exhibit.
Madrigal Pharmaceuticals director Richard S. Levy reported an option exercise and share acquisition. On January 26, 2026, he exercised a stock option for 4,000 shares of Madrigal common stock at an exercise price of $16.46 per share. The option was fully vested and exercisable. Following this transaction, Levy directly owns 25,197 shares of Madrigal common stock, and the reported stock option position was reduced to 0 derivative securities.
Madrigal Pharmaceuticals Chief Commercial Officer Carole Huntsman reported routine share sales. On January 26, 2026, a total of 910 shares of Madrigal common stock were sold in two transactions at prices of $492.42 for 340 shares and $494.59 for 570 shares.
The filing explains that 340 shares were sold by the company on her behalf solely to cover tax withholding tied to vesting restricted stock units and occurred automatically. The 570-share sale was executed under a pre-established Rule 10b5-1 trading plan adopted on November 5, 2024. Following these transactions, Huntsman directly beneficially owns 9,122 shares of Madrigal common stock.
Madrigal Pharmaceuticals insider plans a small stock sale under Rule 144. A person associated with the company filed to sell 340 shares of common stock through Morgan Stanley Smith Barney at an aggregate market value of $163,353 on or about January 26, 2026 on the Nasdaq Stock Market.
The shares come from a restricted stock unit grant that vested on January 23, 2026. Over the prior three months, Carole Huntsman reported additional sales of Madrigal common stock totaling 2,528 shares for gross proceeds of $1,365, - across three transactions.
Madrigal Pharmaceuticals President and CEO William John Sibold reported an automatic sale of company stock related to taxes. On January 26, 2026, 1,577 shares of Madrigal common stock were sold at $492.42 per share. According to the filing, the issuer sold these shares on his behalf solely to cover tax withholding tied to the vesting of restricted stock units, and the sale was not at his discretion. After this transaction, Sibold directly beneficially owned 148,497 shares of Madrigal common stock.
Madrigal Pharmaceuticals insider plans stock sale under Rule 144. A person associated with Madrigal Pharmaceuticals, Inc. (MDGL) has filed a notice of intent to sell 1,577 shares of common stock through Morgan Stanley Smith Barney LLC on or about 01/26/2026 on the Nasdaq Stock Market. The filing lists an aggregate market value of 757,669.65 for these shares and notes that 22,711,420 shares of the company’s common stock were outstanding.
The 1,577 shares to be sold were acquired on 01/23/2026 through a restricted stock unit grant from the issuer that vested on the same date. The notice also reports that over the prior three months, William John Sibold, at the company’s address, sold 2,400 shares of common stock on 12/04/2025 for gross proceeds of 1,380,816.
Madrigal Pharmaceuticals director Rebecca Taub reported an automatic sale of common stock related to taxes on equity compensation. On January 26, 2026, the issuer sold 647 shares of Madrigal common stock on her behalf at $492.42 per share to cover tax withholding obligations from the vesting of restricted stock units. The filing states this sale was automatic and not at her discretion.
After this transaction, Taub beneficially owned 452,704 shares directly and 655,540 shares indirectly through SQN LLC. She and her spouse are managing members of SQN LLC, and she disclaims beneficial ownership of those indirect shares except to the extent of any pecuniary interest.
Madrigal Pharmaceuticals insiders filed a Rule 144 notice covering the planned sale of 647 shares of common stock through Morgan Stanley Smith Barney LLC on the Nasdaq Stock Market, with an aggregate market value of 310851.15. The 647 shares were acquired on 01/23/2026 via a restricted stock unit grant from the issuer, vesting the same day.
The notice also lists prior sales over the past three months. REBECCA A TAUB sold 2238 shares of common stock on 01/20/2026 for gross proceeds of 1098343.26, 18650 shares on 01/09/2026 for 9749391.94, and 18650 shares on 12/10/2025 for 10297573.26. Sales for PAUL A FRIEDMAN include 24800 shares on 01/09/2026 for 12963304.72 and 24800 shares on 12/10/2025 for 13694158.24. The signer represents they are not aware of undisclosed material adverse information about Madrigal’s operations.
An insider has filed a Rule 144 notice for the planned sale of 570 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with an indicated aggregate market value of $273,856.50. The shares relate to restricted stock units acquired on 01/23/2026, and the planned sale date is 01/26/2026 on the NASDAQ. The filing notes that 22,711,420 shares of common stock were outstanding at the time of the notice.
The seller’s recent trading history includes Rule 10b5-1 sales for Carole A Huntsman on 11/21/2025 of 1,064 shares for $590,419.03 in gross proceeds and 894 shares for $492,567.18. By signing, the person for whose account the securities are to be sold represents that they do not know of any material adverse nonpublic information about the issuer’s operations.